Composition for use in preparation of a patient for surgery
Abstract
This record has no abstract on file.
Term
Term ended
Expired 28 April 2026, 0.4 years ago.
- Priority and filed
- Granted
- Expired
- Today
8 claims: 6 independent, 2 dependent
- 1A composition for application to skin, the composition comprising:(a) phenoxyethanol as a biocide;(b) at least one additional biocide selected from the group consisting of chlorhexidine and its salts, halogenated phenols and salts thereof, quaternary ammonium compounds, povidone-iodine, zinc pyridinethione, octenidine dihydrochloride and alcohols;and (c) at least one transcutaneous vehicle selected from the group consisting of alkyl methyl sulfoxides, alkyl pyrrolidones, glycol ethers and glycol esters.
- 4A composition according to any one of the preceding claims wherein the at least one additional biocide includes triclosan.
- 5A composition according to any one of the preceding claims wherein the at least one additional biocide includes chlorhexidine and salts of chlorhexidine selected from the group consisting of gluconate, isethionate, formate, acetate, glutamate, succinamate, monodiglycolate, dimethansulfonate, lactate, diisobutyrate and glucoheptonate salts.
- 6A composition according to any one of the preceding claims wherein the at least one transcutaneous vehicle includes dimethylsulfoxide.
- 7A composition according to any one of the preceding claims wherein the at least one additional biocide includes triclosan and wherein the transcutaneous vehicle is selected from the group consisting of alkyl pyrrolidones and alkyl methyl sulfoxides.
- 8A composition according to any one of the preceding claims further including one or more components serving as a transdermal enhancer, chelating agent, stabiliser, skin emollient, moisturiser, or feel enhancer or the like.
Independent claims6
73 paragraphs in 4 sections, as filed
FIELD OF THE INVENTION
0001The present invention is concerned with a composition suitable for use in a method for preparing a patient for surgery. More particularly, the present invention is concerned with a composition suitable for reducing the risk (in comparison with methods currently employed) of a patient contracting an infection as a result of undergoing a surgical procedure.
0002Although the composition will be herein described with reference to preparation of human patients for surgery it will be understood that the composition is equally applicable to other animals.
BACKGROUND OF THE INVENTION
0003It is usual when preparing a patient for surgery to treat an area surrounding the intended site of an incision by applying a biocide such as iodine or chlorhexidine to the skin surface. This is usually applied immediately preoperatively. After treatment, the area is covered with a sterile sheet or drape leaving an opening through which the surgeon can make an incision and perform an operation. The purpose of this procedure is to kill any colonies of micro-organism which exist on the patient's skin and which may access the surgical site giving rise to infection of the surgical wound. Although this procedure is largely effective in reducing the occurrence of post operative infection, a high proportion of cases in which infection does occur are attributed to autologous infection. Such infection if it does occur may have serious, or even fatal, consequences.
0004It is the practice in some hospitals as an added precaution to ask patients to wash themselves, or at least the areas intended for surgery, with an antiseptic soap once a day for one or two days prior to surgery. This wash is usually done under the shower and is thought to reduce the bacterial load on the patient's skin, and to remove micro-organisms from a wider area of skin than is practical in the operating theatre prior an operation.
0005The above treatments have in common that they are only effective against "transient" micro-organisms. "Transient" micro-organisms are those that exist on the surface of skin. The efficacy of such treatments against transient micro-organisms is discussed by <nplcit id="ncit0001" npl-type="s"><text>Paulson, D. S. (American Journal of Infection Control (1993), 21, 205-209</text></nplcit>) in respect of 4% chlorhexidine gluconate shower baths and <nplcit id="ncit0002" npl-type="s"><text>Byrne, D. J. et al (J. Hospital Infection (1990), 15, 183-187</text></nplcit>) in respect of 4% chlorhexidine detergent. <nplcit id="ncit0003" npl-type="s"><text>Garibaldi, R.A. (J. Hospital Infection (1988), 11, Sup B 5-9</text></nplcit>) showed that 4% chlorhexidine gluconate was more effective than povidone iodine or triclocarban medicated soap for treating skin surface colonization. Nevertheless the frequency of intra-operative wound cultures was at best 4% , i.e. <u>surface cultures</u> were found on 4 patients in 100 intra-operatively.
0006Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
0007The present inventor has observed that while a patient's skin is treated preoperatively with a biocide effective against "transient" micro-organism populations, surgeons are obliged to "scrub up" and this "surgical scrubbing" involves intensive scrubbing treatment with biocides and surfactants extending over several minutes under running water according to complex set down protocols. These scrubbing protocols are intended not only to remove "transient" organisms from the surface of the surgeon's hands, but also to kill "resident" micro-organisms which may reside within pores of the skin. The epidermis which is the outer layer of skin consists of five stratum, of which the stratum corneum is the outermost. Some micro-organisms may reside sub corneum, particularly but not only in sweat glands, hair follicles, and subcutaneous glands. Such "resident" micro-organisms are difficult to kill even with scrubbing and studies have shown that their removal is only partially accomplished by surgical scrubbing. It would be impracticable to scrub patients under running water to the same extent prior to surgery and doing so would only be partially effective
0008The commonly used preoperative compositions result in approximately a reduction of 2 log in "transient" micro-organisms on dry areas of skin, a reduction of 3 log on moist areas of skin (when measured in-vivo on hands and wrists using the "glove juice method" and when measured on fingertips using the "European method"), and have substantially no effect on the population of "resident" micro-organisms in the skin. The occurrence of "resident" micro-organisms varies greatly from one person to another and variations of up to ten fold in resident micro-organism counts can be found in a representative sample of a population. Since the normal preoperative treatment is relatively effective against "transient" micro-organisms, this implies that "resident" micro-organisms may play a role in autologous infection.
0009<nplcit id="ncit0004" npl-type="s"><text>Neilsen et al. (J.Clinical Pat., (1975), 28, 793-797</text></nplcit>) examined the effect of 0.5% chlorhexidine in 62% ethyl alcohol on both superficial "transient" and "resident" flora. They concluded that a two step process including a pre-treatment with a detergent was essential for treating "resident" flora. Of fourteen volunteers examined, sub-corneum aerobic micro-organisms were found in each prior to treatment and remained in at least one case subsequent to the preferred treatment - i.e. a failure rate of 7%. The authors could only conclude that the treatment must be said "to eliminate to a high degree" the patients skin as a source of anaerobic and aerobic operation wound bacteria. Regretfully the intervening 30 years have shown even that conclusion to be unrealistically optimistic and the problem remains.
0010<patcit id="pcit0001" dnum="US9806779W" dnum-type="L"><text>PCT/US98/06779</text></patcit> describes a method for preoperative skin preparation involving iodine and ethyl alcohol in a gel. Although the specification notes that micro-organisms may be "transient' or "resident', it contains no data or claim as to efficacy in respect of "resident" micro-organisms. Although primarily directed to an iodine based composition, the method disclosed (page 26) involves application of the gel to the surgical site immediately preoperatively with scrubbing for about 30 seconds. Both the composition and method differ from that herein disclosed.
0011<patcit id="pcit0002" dnum="WO9853036A1"><text>WO 98/53036 A1</text></patcit> describes an antiseptic cleansing composition comprising an antimicrobial agent, an effective amount of an alkylpolysaccharide surfactant, at least one alkyl alcohol and at least one aryl alcohol.
0012<nplcit id="ncit0005" npl-type="b"><text>Sebben et al: "Surgical antiseptics", Journal Of The American Academy Of Dermatology, C.V. Mosby, vol. 9, no. 5, 1 November 1983, pages 759-765</text></nplcit> describes chlorhexidine as a very safe and effective antiseptic.
0013<patcit id="pcit0003" dnum="US4335115A"><text>US 4,335,115 A</text></patcit> relates to compositions for topical application of erythromycin or erythromycin compounds. The compositions disclosed therein are useful for the treatment of acne.
0014<patcit id="pcit0004" dnum="US4975271A"><text>US 4,975,271 A</text></patcit> relates to the use of a mucosal penetration system for the delivery of chemotherapeutic agents (i.e. drug or bioactive agent) to localized sites in the mouth for the treatment of periodontal disease. The method of treatment involves the placement of a chemotherapeutic agent into the periodontal pocket in conjunction with a skin-penetration enhancer that enables the agent to penetrate into the infected gingival tissue.
0015<nplcit id="ncit0006" npl-type="s"><text>Nielsen M.L. et al.: "Anaerobic and aerobic skin bacteria before and after skin disinfection with chlorhexidine: An experimental study in volunteers", Journal Of Clinical Pathology, vol. 28, 1975, pages 793-797</text></nplcit> describes a volunteer study relating to the amount, composition, and localization of anaerobic and aerobic bacteria in the normal skin before and after disinfection.
0016<patcit id="pcit0005" dnum="WO9844930A"><text>WO 98/44930</text></patcit> describes antimicrobial skin-preparations useable to disinfect a surgical site for surgery. The antimicrobial skin-preparation formula includes iodine, alcohol and gel.
0017<nplcit id="ncit0007" npl-type="s"><text>Paulson D.S.: "Efficacy of a 4% chlorhexidine gluconate as a full-body shower wash", American Journal Of Infection Control, vol. 21, 1993, pages 205-209</text></nplcit> describes use of 4% chlorhexidine gluconate in a shower bath application to evaluate its merits in reducing resident skin microorganisms.
0018<nplcit id="ncit0008" npl-type="s"><text>Ritter M.A. et al.: "The antimicrobial effectiveness of operative-site preoperative agents: a microbiological and clinical study", Journal Of Bone And Joint Surgery, vol. 62, no. 5, 1980, pages 826-828</text></nplcit> describes evaluation of eight wound preparative agents (one triclosan compound, one hexachlorophene compound, and six iodophors) under actual operating-room conditions for efficacy in de-germing the operative site prior to the performance of total hip arthroplasties.
0019<patcit id="pcit0006" dnum="WO0141573A1"><text>WO 01/41573 A1</text></patcit> describes antimicrobial compositions (e.g. gels), comprising at least 30 % alcohol and/or triclosan in combination with phenoxyethanol, benzalkonium or benzethonium chloride, cocophosphatidyl-dimoniun chloride and plant extracts for disinfecting skin.
0020<patcit id="pcit0007" dnum="WO0015036A1"><text>WO 00/15036 A1</text></patcit> describes a topical antimicrobial composition containing an antimicrobial complex that provides sustained antimicrobial disinfecting action upon contact with microorganisms for prolonged periods, without the necessity for reapplication.
0021<patcit id="pcit0008" dnum="WO03034994A2"><text>WO 03/034994 A2</text></patcit> describes antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations
0022<patcit id="pcit0009" dnum="WO0141567A1"><text>WO 01/41567 A1</text></patcit> describes antimicrobial compositions comprised of the antimicrobial components a) an alcohol and b) a cationic quaternary ammonium compound, phenoxy ethanol and optionally a biguanide compound and c) a combination of surfactants that do not include anionic surfactants.
0023<nplcit id="ncit0009" npl-type="s"><text>S Pandey et al: "Development and evaluation of transdermal formulations containing metronidazole and norfloxacin for the treatment of burn wound", Indian Journal of Experimental Biology, 1 May 1999, pages 450-454</text></nplcit> describes topical ointments containing metronidazole and norfloxacin in different bases.
0024<patcit id="pcit0010" dnum="ZA9907202A"><text>ZA 9 907 202 A</text></patcit> describes composition for topical application, which includes an active substance in the form of micro-droplets of water-insoluble liquid.
0025<patcit id="pcit0011" dnum="WO2004082649A1"><text>WO 2004/082649 A1</text></patcit> describes a composition comprising an effective amount of pyrithione or a polyvalent metal salt of a pyrithione and an effective amount of a zinc-containing layered material which provides an augmentation factor greater than 1. <patcit id="pcit0012" dnum="WO2004082649A1"><text>WO 2004/082649 A1</text></patcit> further describes a method of treating microbial infections, fungal infections, or treating dandruff comprising the use of the composition.
0026It is also critically important to note that in the cited examples the primary biocides are chlorhexidine or iodine and with those biocides little, if any, subcutaneous penetration is possible because of the strong interactions between these biocidal actives and all body proteins. In the case of chlorhexidine these interactions cause the biocide to become attached (substantive) to the protein and in the case of iodine cause it to be deactivated by the protein. Therefore any subcutaneous action is dependant upon the ethanol contained therein.
0027This penetrating ethanol is quickly dissipated within the body and therefore there is no residual biocidal activity sub corneum beyond a few minutes. Recolonisation of these areas begins immediately after alcohol dissipation. Most surgical procedures take between 15 minutes and six hours.
0028Because of the currently perceived risk of post operative infection (including autologous infection) surgeons today routinely prescribe preoperative antibiotics as a prophylactic measure. This practice risks increasing the resistance of micro-organisms to antibiotics and is a major medical and social concern.
0029It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art. It is an object of preferred embodiments of the invention to provide improved compositions for use in methods of preparing a patient for surgery, compositions which in highly preferred embodiments are more effective at reducing post operative infection than one or more prior art compositions.
BRIEF STATEMENT OF INVENTION
0030The present inventor has found that a preparation including one or more biocides and a transcutaneous vehicle effective to carry the biocide as a solution across the dermal barrier is effective to kill the "resident" micro-organisms especially when applied repeatedly several times a day over several days preceding an operation. Desirably the composition is applied as a gel or cream and spread over a relevant area of skin. The composition may be self applied by the patient on instruction by the surgeon and will usually be left in place until a subsequent application.
0031According to a first aspect of the invention,a composition is provided for application to skin, the composition comprising: <ol id="ol0001" compact="compact"><li>(a) phenoxyethanol as a biocide;</li><li>(b) at least one additional biocide selected from the group consisting of chlorhexidine and its salts, halogenated phenols and salts thereof, quaternary ammonium compounds, povidone-iodine, zinc pyridinethione, octenidine dihydrochloride and alcohols; and</li><li>(c) at least one transcutaneous vehicle selected from the group consisting of alkyl methyl sulfoxides, alkyl pyrrolidones, glycol ethers and glycol esters.</li></ol>
0032The present specification describes a composition for application to skin comprising at least one biocide and at least one transcutaneous vehicle effective to convey the biocide to "resident" micro-organisms.
0033The transcutaneous vehicle is selected from the group consisting of suitable alkyl methyl sulfoxides, alkyl pyrrolidones, glycol ethers and glycol esters.
0034The "resident" micro-organisms may be sub epidermal.
0035"Transcutaneous" in respect of the vehicle means that the vehicle penetrates at least to the subcutis and desirable through the subcutis. Skin is the largest human organ and consists of three functional layers: epidermis, dermis, and subcutis. Skin is designed to protect the organism from water loss and mechanical, chemical, microbial, and physical penetration and is specially structured to achieve these tasks. Those skilled in the art will recognise that while ethanol and similar alkyl alcohols have some ability to penetrate into the corneum, they are not transcutaneous and do not penetrate to the subcutis. Transcutaneous vehicles have been developed for transporting systemic drugs across the skin barrier, but have not previously been used to transport biocides into skin.
0036Combinations of biocides are used in the invention and an especially preferred combination is triclosan with phenoxyethanol. Care needs to be taken that in the concentrations used the biocides have no adverse systemic effect
0037The present specification also describes a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both "transient" and "resident" micro-organisms. Preferred embodiments employ a composition according to the first aspect and leave virtually no surviving "resident" or "transient" micro-organisms.
0038The term "comprising" is herein used in an inclusive sense that is to say in the sense of "including" or "containing". The term is not intended in an exclusive sense ("consisting of' or "composed of').
0039The composition contains a combination of biocides and these are formulated so as to be able to access subcutaneous "resident" micro-organisms. The method decribed herein is used in conjunction with prior art methods of preparation including showering with antibacterial soap and skin prepping on the operating table. It is not intended that the method be used as a substitute for skin prepping.
0040The present specification further describes a method, wherein said step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision is repeated at least once, during the 24 hours preceding an operation.
0041Preferably, the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision is repeated at least once a day for several days prior to the operation.
0042Suitable biocides for use in compositions according to the invention include, without limitation, chlorhexidine and its salts; dichlorophene, other chlorophenol derivatives such as p-chloro-m-xylenol, chlorophene and 2,4,4-trichloro-2-hydroxydiphenylether (triclosan); or any other salt thereof, quaternary ammonium compounds, povidone-iodine, zinc pyridinethione, octenidine dihydrochloride, o-phenylphenol, and phenoxy ethanol.
0043Suitable salts of chlorhexidine include the gluconate, isethionate, formate, acetate, glutamate, succinamate, monodiglycolate, dimethanesulfonate, lactate, diisobutyrate or the glucoheptonate salts.
0044Other suitable biocides include selected alcohols such as ethyl, methyl, isopropyl and phenyl alcohol.
0045Preferably the antimicrobial agent has a water solubility of at least 0.001% w/v at ambient temperature.
0046When the antimicrobial agent is chlorhexidine digluconate it is used in an amount preferably not exceeding 4.5% w/v. When the antimicrobial agent is 2,4,4-trichloro-2-hydroxydiphenylether (triclosan) it is used in an amount preferably not exceeding 3% w/v. Biocides such as iodine compounds and chlorhexidine compounds react with protein and are not suitable for dermal penetration since they would be deactivated by skin protein, but are effective against "transient" micro-organisms. Combinations of triclosan with phenoxy ethanol have been found to be unexpectedly effective for use in the invention and exhibit a desirable synergy.
0047Compositions according to the invention may be formulated into a liquid, lotion, cream, gel, or other topical vehicle, or may be formulated as a spray. The composition can be aqueous or alcoholic utilising ethanol, n-propanol or isopropanol.
0048In addition to biocides, the formulation includes at least one vehicle in which the biocides are soluble and which is effective to transport the biocides transdermally. The vehicle is selected from the group consisting of suitable alkyl methyl sulfoxides, alkyl pyrrolidones, glycol ethers and suitable esters. Examples of such vehicles include, without limitation, dimethyl sulfoxide as an example of a suitable alkyl methyl sulfoxide; N-methyl-2- pyrrolidone as an example of a suitable alkyl pyrrolidone; isopropylmyristate as an example of a suitable ester and diethylene glycol monoethyl ether as an example of a suitable glycol ether. The use of sulfoxides may require medical prescription in some jurisdictions.
PREFERRED EMBODIMENTS OF THE INVENTION
0049Preferred embodiments of the invention will now be described by way of example only.
0050<b>Example 1:</b> A gel suitable for application to skin according to the invention. <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="39mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><tbody><row><entry>Ethanol:</entry><entry>70.00% w/w</entry></row><row><entry>Water</entry><entry>10.39%</entry></row><row><entry>Hydroxypropyl cellulose</entry><entry>0.60%</entry></row><row><entry>Phenoxy ethanol</entry><entry>2.00%</entry></row><row><entry>Triclosan</entry><entry>1.00%</entry></row><row><entry>Dimethylsulfoxide</entry><entry>10.00%</entry></row><row><entry>Propylene Glycol</entry><entry>5.00%</entry></row><row><entry>Isopropylmyristate</entry><entry>1.00%</entry></row><row><entry>Dyestuff</entry><entry>0.01%</entry></row></tbody></tgroup></table></tables>
0051In example 1 the ethanol serves as a biocide for transient organisms, as a skin penetrant, a solvent, and as a drying aid. Water acts as a solvent, and activator of ethanol as biocide. Hydroxypropyl cellulose acts as a gelling agent. Phenoxy ethanol acts as a preservative and as a secondary biocide for transient and subcutaneous micro-organisms. Triclosan acts as the primary biocide for killing transient and subcutaneous micro-organisms. Dimethylsulfoxide is the transcutaneous vehicle. Propylene Glycol also acts as a transcutaneous vehicle. Isopropylmyristate also acts as a transcutaneous vehicle and skin emollient. Dyestuff is added as an indicator that the required area of skin has been appropriately treated.
0052An example of a suitable method involves a patient being instructed by the patient's surgeon to spread the gel of Example 1 over an area of the skin covering at least a margin of about 5cm around the site of intended incision in all directions at a rate of from about 0.03 to 0.1 g / sq. cm. of skin surface. The gel should be rubbed into the skin twice per day at 8 hr intervals for three days prior to the date of the operation and once applied should be left in place and desirably should not be washed off.
0053<b>Example 2:</b> An embodiment of a cream according to the invention and suitable for use in a method as described herein has the following composition. The main function of each component is indicated in the table. <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="83mm" /><colspec colnum="3" colname="col3" colwidth="21mm" /><colspec colnum="4" colname="col4" colwidth="32mm" /><thead><row><entry align="center" valign="top">Commercial name</entry><entry align="center" valign="top">Chemical name</entry><entry align="center" valign="top">Contents (%w/w)</entry><entry align="center" valign="top">Function</entry></row></thead><tbody><row><entry valign="bottom">BPO</entry><entry valign="bottom">Benzoyl peroxide</entry><entry align="right" valign="bottom">5.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Irgasan DP300</entry><entry valign="bottom">Triclosan</entry><entry align="right" valign="bottom">1.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Pharmasolv</entry><entry valign="bottom">N - Methyl pyrrolidone</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Transdermal enhancer</entry></row><row><entry valign="bottom">EDTA 2Na</entry><entry valign="bottom">Disodium Ethylene Diamine Tetra Acetic Acid</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Chelating agent, stabiliser</entry></row><row><entry valign="bottom">Glycerol</entry><entry valign="bottom">Glycerol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Carbopol 940</entry><entry valign="bottom">Carbomer(Acrylic copolymer)</entry><entry align="right" valign="bottom">0.90%</entry><entry valign="bottom">Viscosity modifier</entry></row><row><entry valign="bottom">Pentane - DB</entry><entry valign="bottom">Benzyl benzoate</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Skin emollient</entry></row><row><entry valign="bottom">DPG</entry><entry valign="bottom">Dipropylene glycol</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Crodasinic LS30</entry><entry valign="bottom">Sodium Lauroyl Sarcosinate(30%)</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emulsifier</entry></row><row><entry valign="bottom">Promulgen - G</entry><entry valign="bottom">Stearyl alcohol (and) Polyethyleneglycol 1000 cetyl/stearyl ether</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emollient/emulsifier</entry></row><row><entry valign="bottom">PVP K-15</entry><entry valign="bottom">Polyvinylpyrrolidone</entry><entry align="right" valign="bottom">0.10%</entry><entry valign="bottom">Skin feel enhancer</entry></row><row><entry valign="bottom">Phenoxyethanol</entry><entry valign="bottom">Phenoxyethanol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Active - secondary biocide</entry></row><row><entry valign="bottom">TEA 99%</entry><entry valign="bottom">Triethanolamine</entry><entry align="right" valign="bottom">0.19%</entry><entry valign="bottom">pH modifier</entry></row><row><entry valign="bottom">Ethanol 100%</entry><entry valign="bottom">Ethyl alcohol</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Solvent/formulation aid</entry></row><row><entry valign="bottom">P-water</entry><entry valign="bottom">Water</entry><entry align="right" valign="bottom">55.80%</entry><entry valign="bottom">Solvent</entry></row><row><entry valign="bottom" /><entry valign="bottom">Dyestuff</entry><entry align="right" valign="bottom">0.01%</entry><entry valign="bottom">Treatment marker</entry></row><row><entry valign="bottom" /><entry valign="bottom">TOTAL</entry><entry align="right" valign="bottom">100.00%</entry><entry valign="bottom" /></row></tbody></tgroup></table></tables>
0054In use a patient is instructed by the patient's surgeon to spread the cream of Example 2 over an area of the skin covering at least a margin of about 5cm around the site of intended incision in all directions at a rate of from about 0.03 to 0.1 g / sq. cm. of skin surface. The cream should be rubbed into the skin at least twice per day (preferably at 8 hr intervals) for three days prior to the date of the operation and, once applied, should be left in place.
0055<b>Example 3:</b> A second embodiment of a cream according to the invention and suitable for use in a method as described herein has the following composition. The main function of each component is indicated. <tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="66mm" /><colspec colnum="3" colname="col3" colwidth="30mm" /><colspec colnum="4" colname="col4" colwidth="39mm" /><thead><row><entry align="center" valign="top"><b>Commercial name</b></entry><entry align="center" valign="top"><b>Chemical name</b></entry><entry align="center" valign="top"><b>Contents (%w/w)</b></entry><entry align="center" valign="top"><b>Function</b></entry></row></thead><tbody><row><entry valign="bottom">BPO</entry><entry valign="bottom">Benzoyl peroxide</entry><entry align="right" valign="bottom">5.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Irgasan DP300</entry><entry valign="bottom">Triclosan</entry><entry align="right" valign="bottom">1.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Trancutol P</entry><entry valign="bottom">Diethylene Glycol Monoethyl Ether</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Transdermal enhancer</entry></row><row><entry valign="bottom">EDTA 2Na</entry><entry valign="bottom">Disodium Ethylene Diamine Tetra Acetic Acid</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Chelating agent, stabiliser</entry></row><row><entry valign="bottom">Glycerol</entry><entry valign="bottom">Glycerol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Carbopol 940</entry><entry valign="bottom">Carbomer(Acrylic copolymer)</entry><entry align="right" valign="bottom">0.90%</entry><entry valign="bottom">Viscosity modifier</entry></row><row><entry valign="bottom">Pentane - DB</entry><entry valign="bottom">Benzyl benzoate</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Skin emollient</entry></row><row><entry valign="bottom">DPG</entry><entry valign="bottom">Dipropylene glycol</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Crodasinic LS30</entry><entry valign="bottom">Sodium Lauroyl Sarcosinate(30%)</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emulsifier</entry></row><row><entry valign="bottom">Promulgen - G</entry><entry valign="bottom">Stearyl alcohol (and)</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emollient/emulsifier</entry></row><row><entry valign="bottom" /><entry valign="bottom">Polyethyleneglycol 1000 cetyl/stearyl ether</entry><entry align="right" valign="bottom" /><entry valign="bottom" /></row><row><entry valign="bottom">PVP K-15</entry><entry valign="bottom">Polyvinylpyrrolidone</entry><entry align="right" valign="bottom">0.10%</entry><entry valign="bottom">Skin feel enhancer</entry></row><row><entry valign="bottom">Phenoxyethanol</entry><entry valign="bottom">Phenoxyethanol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Active - secondary biocide</entry></row><row><entry valign="bottom">TEA 99%</entry><entry valign="bottom">Triethanolamine</entry><entry align="right" valign="bottom">0.19%</entry><entry valign="bottom">pH modifier</entry></row><row><entry valign="bottom">Ethanol 100%</entry><entry valign="bottom">Ethyl alcohol</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Solvent/formulation aid</entry></row><row><entry valign="bottom">P-water</entry><entry valign="bottom">Water</entry><entry align="right" valign="bottom">55.80%</entry><entry valign="bottom">Solvent</entry></row><row><entry /><entry>Dyestuff</entry><entry align="right">0.01%</entry><entry>Treatment marker</entry></row><row><entry /><entry>TOTAL</entry><entry align="right">100.00%</entry><entry /></row></tbody></tgroup></table></tables>
0056The cream of example 3 is applied in a similar manner as described above with reference to example 1 or 2.
0057<b>Example 4:</b> A third embodiment of a cream according to the invention and suitable for use in a method as described herein has the following composition. The main function of each component is indicated in the following table. <tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="82mm" /><colspec colnum="3" colname="col3" colwidth="21mm" /><colspec colnum="4" colname="col4" colwidth="32mm" /><thead><row><entry align="center" valign="top"><b>Commercial name</b></entry><entry align="center" valign="top"><b>Chemical name</b></entry><entry align="center" valign="top"><b>Contents (%w/w)</b></entry><entry align="center" valign="top"><b>Function</b></entry></row></thead><tbody><row><entry valign="bottom">BPO</entry><entry valign="bottom">Benzoyl peroxide</entry><entry align="right" valign="bottom">5.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Irgasan DP300</entry><entry valign="bottom">Triclosan</entry><entry align="right" valign="bottom">1.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Pharmasolv</entry><entry valign="bottom">N - Methyl pyrrolidone</entry><entry align="right" valign="bottom">5.00%</entry><entry valign="bottom">Transdermal enhancer</entry></row><row><entry valign="bottom">Trancutol P</entry><entry valign="bottom">Diethylene Glycol Monoethyl Ether</entry><entry align="right" valign="bottom">5.00%</entry><entry valign="bottom">Transdermal enhancer</entry></row><row><entry valign="bottom">EDTA 2Na</entry><entry valign="bottom">Disodium Ethylene Diamine Tetra Acetic Acid</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Chelating agent, stabiliser</entry></row><row><entry valign="bottom">Glycerol</entry><entry valign="bottom">Glycerol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Carbopol 940</entry><entry valign="bottom">Carbomer(Acrylic copolymer)</entry><entry align="right" valign="bottom">0.90%</entry><entry valign="bottom">Viscosity modifier</entry></row><row><entry valign="bottom">Pentane - DB</entry><entry valign="bottom">Benzyl benzoate</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Skin emollient</entry></row><row><entry valign="bottom">DPG</entry><entry valign="bottom">Dipropylene glycol</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Crodasinic LS30</entry><entry valign="bottom">Sodium Lauroyl Sarcosinate(30%)</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emulsifier</entry></row><row><entry valign="bottom">Promulgen - G</entry><entry valign="bottom">Stearyl alcohol (and) Polyethyleneglycol 1000 cetyl/stearyl ether</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emollient/emulsifier</entry></row><row><entry valign="bottom">PVP K-15</entry><entry valign="bottom">Polyvinylpyrrolidone</entry><entry align="right" valign="bottom">0.10%</entry><entry valign="bottom">Skin feel enhancer</entry></row><row><entry valign="bottom">Phenoxyethanol</entry><entry valign="bottom">Phenoxyethanol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Active - secondary biocide</entry></row><row><entry valign="bottom">TEA 99%</entry><entry valign="bottom">Triethanol amine</entry><entry align="right" valign="bottom">0.19%</entry><entry valign="bottom">pH modifier</entry></row><row><entry valign="bottom">Ethanol 100%</entry><entry valign="bottom">Ethyl alcohol</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Solvent/formulation aid</entry></row><row><entry valign="bottom">P-water</entry><entry valign="bottom">Water</entry><entry align="right" valign="bottom">55.80%</entry><entry valign="bottom">Solvent</entry></row><row><entry valign="bottom" /><entry valign="bottom">Dyestuff</entry><entry align="right" valign="bottom">0.01%</entry><entry valign="bottom">Treatment marker</entry></row><row><entry valign="bottom" /><entry valign="bottom">TOTAL</entry><entry align="right" valign="bottom">100.00%</entry><entry valign="bottom" /></row></tbody></tgroup></table></tables>
0058The cream of example 4 is applied in a similar manner as described above with reference to examples 1, 2 or 3.
0059In each of the previous examples it is preferable for the patient in addition to the treatments described to shower or conduct a whole body wash using a disinfecting soap on the day of, and prior to, the operation
0060<b>Example 5:</b> Relative efficacy.
0061The transcutaneous penetration and comparative release of active ingredient were compared using a horizontal glass Franz-type diffusion cells such as are described in <nplcit id="ncit0010" npl-type="s"><text>R. Danids, (Skin Care Forum, Issue 37, August 2004, Cognis</text></nplcit>) ; <nplcit id="ncit0011" npl-type="b"><text>S. Jung, (The University of California Irvine Undergraduate Research Journal, p. 25-26, Vol V, 2002, University of California Irvine</text></nplcit>); <nplcit id="ncit0012" npl-type="b"><text>Guideline for Industry Non-sterile Semisolid Dosage Forms(SUPAC-SS CMC7), May 1997, U.S. Department of Health and Human Services FDA CDER</text></nplcit>. A standard cellophane dialysis membrane of MW cut off 6-8000 was used for the diffusion studies. The Franz cell receiving solution was composed of 50% v/v methanol/ water. Cellophane membranes were mounted horizontally in the Franz cells. 0.5 g of sample were used for each test. The cell receptor was continuously stirred magnetically and maintained at 35 +/-2 °C. At the designated time 150microlitre aliquots were sampled from the receiving vessel of the Franz cells. 20 microliters were injected into HLPC. The residue was returned to the Franz -cell and the cells topped up with additional receiving solution.
00620.5 g samples of compositions according to examples 2, 3 and 4 were compared over periods of 2, 4 and 7 hours with a prior art composition comprising 5% chlorhexidine in 62% ethyl alcohol. The active ingredient was increased from 0.5% to 5% for the purposes of comparison with examples 2-4. Each test was in duplicate. HLPC analysis was performed using a C18 column, mobile phase 75% methanol, flow rate 1.5 mL/min. detector -UV 270nm. The mean result of duplicate tests is tabulated below. Column A shows the composition example number, column B shows the time in hours. Column C, D, and E give the results for the actives in the respective formulations, both in mg and as a % of the sample quantity tested. <tables id="tabl0005" num="0005"><table frame="all"><tgroup cols="8"><colspec colnum="1" colname="col1" colwidth="23mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="17mm" /><colspec colnum="4" colname="col4" colwidth="17mm" /><colspec colnum="5" colname="col5" colwidth="15mm" /><colspec colnum="6" colname="col6" colwidth="12mm" /><colspec colnum="7" colname="col7" colwidth="15mm" /><colspec colnum="8" colname="col8" colwidth="15mm" /><thead><row><entry align="center" valign="top">A</entry><entry align="center" valign="top">B</entry><entry namest="col3" nameend="col4" align="center" valign="top">C</entry><entry namest="col5" nameend="col6" align="center" valign="top">D</entry><entry namest="col7" nameend="col8" align="center" valign="top">E</entry></row><row><entry align="center" valign="top">Example no.</entry><entry align="center" valign="top">time</entry><entry namest="col3" nameend="col4" align="center" valign="top">phenoxyethanol</entry><entry namest="col5" nameend="col6" align="center" valign="top">triclosan</entry><entry namest="col7" nameend="col8" align="center" valign="top">chlorhexidine</entry></row><row><entry align="center" valign="top" /><entry align="center" valign="top">(hrs)</entry><entry align="center" valign="top">mg</entry><entry align="center" valign="top">%</entry><entry align="center" valign="top">mg</entry><entry align="center" valign="top">%</entry><entry align="center" valign="top">mg</entry><entry align="center" valign="top">%</entry></row></thead><tbody><row><entry align="center">2</entry><entry align="center">2</entry><entry align="center">0.6865</entry><entry align="center">13.73</entry><entry align="center">0.0119</entry><entry align="center">0.24</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center">4</entry><entry align="center">1.0745</entry><entry align="center">21.49</entry><entry align="center">0.0246</entry><entry align="center">0.49</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center">7</entry><entry align="center">1.4970</entry><entry align="center">29.94</entry><entry align="center">0.038</entry><entry align="center">0.76</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /></row><row><entry align="center">3</entry><entry align="center">2</entry><entry align="center">0.6495</entry><entry align="center">12.99</entry><entry align="center">0.0103</entry><entry align="center">0.21</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center">4</entry><entry align="center">1.0150</entry><entry align="center">20.3</entry><entry align="center">0.0201</entry><entry align="center">0.40</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center">7</entry><entry align="center">1.4080</entry><entry align="center">28.16</entry><entry align="center">0.0331</entry><entry align="center">0.66</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /></row><row><entry align="center">4</entry><entry align="center">2</entry><entry align="center">0.3355</entry><entry align="center">6.71</entry><entry align="center">0.0131</entry><entry align="center">0.26</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center">4</entry><entry align="center">0.9960</entry><entry align="center">19.92</entry><entry align="center">0.0241</entry><entry align="center">0.48</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center">7</entry><entry align="center">1.3645</entry><entry align="center">27.29</entry><entry align="center">0.0388</entry><entry align="center">0.78</entry><entry align="center" /><entry align="center" /></row><row><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /></row><row><entry align="center">5</entry><entry align="center">2</entry><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center">0.0026</entry><entry align="center">0.052</entry></row><row><entry align="center" /><entry align="center">4</entry><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center">0.0027</entry><entry align="center">0.054</entry></row><row><entry align="center" /><entry align="center">7</entry><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center" /><entry align="center">0.0039</entry><entry align="center">0.078</entry></row></tbody></tgroup></table></tables>
0063It can be seen that phenoxy ethanol penetrates at a very much faster rate than either of the other biocides and to a much greater extent. After 2 hours more than 13 % has penetrated compared with 0.24% of triclosan and even less of chlorhexidine. The difference is more substantial after 7 hrs. The penetration of biocides was much greater than for the prior art.
0064<b>Example 6:</b> Synergism between triclosan and phenoxy ethanol
0065An aqueous handwash formulation was prepared with three differing actives. Formula 1 contained triclosan 1% alone, formula 2 phenoxyethanol 2% alone, formula 3 triclosan 1% in combination with phenoxyethanol 2%. The three formulations were tested against an inoculum of Pseudomonas aeruginosa against which triclosan alone is known to be relatively ineffective. The results were as follows: <tables id="tabl0006" num="0006"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="24mm" /><colspec colnum="2" colname="col2" colwidth="41mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="39mm" /><colspec colnum="5" colname="col5" colwidth="39mm" /><thead><row><entry><b>Formulation</b></entry><entry><b>Active ingredients</b></entry><entry><b>Initial conc. ATTC 15442</b></entry><entry><b>Reduction at 30 secs contact</b></entry><entry><b>Reduction at 60 secs contact</b></entry></row></thead><tbody><row><entry>formula 1</entry><entry>Triclosan 1%</entry><entry>1.2 x log 7</entry><entry>9.2 x log 2</entry><entry>3.0 log 3</entry></row><row><entry>formula 2</entry><entry>Phenoxyethanol 2%</entry><entry>6.8 x log 6</entry><entry>1.2 log 2</entry><entry>3.0 log 3</entry></row><row><entry>formula 3</entry><entry>Triclosan 1% & Phenoxyethanol 2%</entry><entry /><entry>1.2 log 7 (total kill)</entry><entry>1.2 log 7 (total kill)</entry></row></tbody></tgroup></table></tables>
0066This data demonstrates a synergistic interaction between triclosan and phenoxy ethanol. This is particularly advantageous in the present case since the data in example 5 shows that phenoxyethanol penetrates at about 40 times the rate that triclosan alone or chlorhexidine alone would penetrate. In view of this data it is predictable that no subdermal micro-organisms would survive treatment over 2 hours, although repetitive treatment and treatment over longer periods would clearly be preferable.
0067<b>Example 7:</b> Cream employing CHG/phenoxyethanol as actives
0068In this case the CHG is effective only against transient micro-organisms and the cream relies upon phenoxyethanol against resident micro-organisms. <tables id="tabl0007" num="0007"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="82mm" /><colspec colnum="3" colname="col3" colwidth="21mm" /><colspec colnum="4" colname="col4" colwidth="32mm" /><thead><row><entry align="center" valign="top"><b>Commercial name</b></entry><entry align="center" valign="top"><b>Chemical name</b></entry><entry align="center" valign="top"><b>Contents (%w/w)</b></entry><entry align="center" valign="top"><b>Function</b></entry></row></thead><tbody><row><entry valign="bottom" /><entry valign="bottom">CHG</entry><entry align="right" valign="bottom">1.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Pharmasolv</entry><entry valign="bottom">N - Methyl pyrrolidone</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Transdermal enhancer</entry></row><row><entry valign="bottom">EDTA 2Na</entry><entry valign="bottom">Disodium Ethylene Diamine Tetra Acetic Acid</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Chelating agent, stabiliser</entry></row><row><entry valign="bottom">Glycerol</entry><entry valign="bottom">Glycerol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Carbopol 940</entry><entry valign="bottom">Carbomer(Acrylic copolymer)</entry><entry align="right" valign="bottom">0.90%</entry><entry valign="bottom">Viscosity modifier</entry></row><row><entry valign="bottom">Pentane - DB</entry><entry valign="bottom">Benzyl benzoate</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Skin emollient</entry></row><row><entry valign="bottom">DPG</entry><entry valign="bottom">Dipropylene glycol</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Crodasinic LS30</entry><entry valign="bottom">Sodium Lauroyl Sarcosinate(30%)</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emulsifier</entry></row><row><entry valign="bottom">Promulgen - G</entry><entry valign="bottom">Stearyl alcohol (and) Polyethyleneglycol 1000 cetyl/stearyl ether</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emollient/emulsifier</entry></row><row><entry valign="bottom">PVP K-15</entry><entry valign="bottom">Polyvinylpyrrolidone</entry><entry align="right" valign="bottom">0.10%</entry><entry valign="bottom">Skin feel enhancer</entry></row><row><entry valign="bottom">Phenoxyethanol</entry><entry valign="bottom">Phenoxyethanol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Active - secondary biocide</entry></row><row><entry valign="bottom">TEA 99%</entry><entry valign="bottom">Triethanol amine</entry><entry align="right" valign="bottom">0.19%</entry><entry valign="bottom">pH modifier</entry></row><row><entry valign="bottom">Ethanol 100%</entry><entry valign="bottom">Ethyl alcohol</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Solvent/formulation aid</entry></row><row><entry valign="bottom">P-water</entry><entry valign="bottom">Water</entry><entry align="right" valign="bottom">55.80%</entry><entry valign="bottom">Solvent</entry></row><row><entry valign="bottom" /><entry valign="bottom">Dyestuff</entry><entry align="right" valign="bottom">0.01%</entry><entry align="center" valign="bottom">Treatment marker</entry></row><row><entry valign="bottom" /><entry valign="bottom">TOTAL</entry><entry align="right" valign="bottom">100.00%</entry><entry valign="bottom" /></row></tbody></tgroup></table></tables>
0069<b>Example 8 Cream employing povidone iodine/phenoxyethanol as actives</b><tables id="tabl0008" num="0008"><table frame="all"><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="82mm" /><colspec colnum="3" colname="col3" colwidth="21mm" /><colspec colnum="4" colname="col4" colwidth="32mm" /><thead><row><entry align="center" valign="top"><b>Commercial name</b></entry><entry align="center" valign="top"><b>Chemical name</b></entry><entry align="center" valign="top"><b>Contents (%w/w)</b></entry><entry align="center" valign="top"><b>Function</b></entry></row></thead><tbody><row><entry valign="bottom" /><entry valign="bottom">Povidone -iodine</entry><entry align="right" valign="bottom">6.00%</entry><entry valign="bottom">Actives</entry></row><row><entry valign="bottom">Pharmasolv</entry><entry valign="bottom">N - Methyl pyrrolidone</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Transdermal enhancer</entry></row><row><entry valign="bottom">EDTA 2Na</entry><entry valign="bottom">Disodium Ethylene Diamine Tetra Acetic Acid</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Chelating agent, stabiliser</entry></row><row><entry valign="bottom">Glycerol</entry><entry valign="bottom">Glycerol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Carbopol 940</entry><entry valign="bottom">Carbomer(Acrylic copolymer)</entry><entry align="right" valign="bottom">0.90%</entry><entry valign="bottom">Viscosity modifier</entry></row><row><entry valign="bottom">Pentane - DB</entry><entry valign="bottom">Benzyl benzoate</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Skin emollient</entry></row><row><entry valign="bottom">DPG</entry><entry valign="bottom">Dipropylene glycol</entry><entry align="right" valign="bottom">3.00%</entry><entry valign="bottom">Moisturiser</entry></row><row><entry valign="bottom">Crodasinic LS30</entry><entry valign="bottom">Sodium Lauroyl Sarcosinate(30%)</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emulsifier</entry></row><row><entry valign="bottom">Promulgen - G</entry><entry valign="bottom">Stearyl alcohol (and) Polyethyleneglycol 1000 cetyl/stearyl ether</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Emollient/ emulsifier</entry></row><row><entry valign="bottom">PVP K-15</entry><entry valign="bottom">Polyvinylpyrrolidone</entry><entry align="right" valign="bottom">0.10%</entry><entry valign="bottom">Skin feel enhancer</entry></row><row><entry valign="bottom">Phenoxyethanol</entry><entry valign="bottom">Phenoxyethanol</entry><entry align="right" valign="bottom">2.00%</entry><entry valign="bottom">Active - secondary biocide</entry></row><row><entry valign="bottom">TEA 99%</entry><entry valign="bottom">Triethanol amine</entry><entry align="right" valign="bottom">0.19%</entry><entry valign="bottom">pH modifier</entry></row><row><entry valign="bottom">Ethanol 100%</entry><entry valign="bottom">Ethyl alcohol</entry><entry align="right" valign="bottom">10.00%</entry><entry valign="bottom">Solvent/ formulation aid</entry></row><row><entry valign="bottom">P-water</entry><entry valign="bottom">Water</entry><entry align="right" valign="bottom">50.81%</entry><entry valign="bottom">Solvent</entry></row><row><entry valign="bottom" /><entry valign="bottom">TOTAL</entry><entry align="right" valign="bottom">100.00%</entry><entry valign="bottom" /></row></tbody></tgroup></table></tables>
0070In this case the povidone iodine is effective only against transient micro-organisms and the cream relies upon phenoxyethanol against resident micro-organisms. The combination of triclosan with phenoxyethanol is preferred because the triclosan is persistently effective against transient micro-organisms (high residual activity) and also is persistent when transported sub cutaneously where it acts synergistically with the phenoxyethanol against resident micro-organisms.
0071The amount of gel applied will of course vary according to the formulation and the total area to be treated. Likewise, the frequency of application and the number of days prior the operation on which it should be applied as well as the exact area of application will vary with the formulation, skin type etc. and will need to be determined for each formulation in accordance with the invention by the surgeon in accordance with "best practice" guidelines. The determination of such protocols is a matter of routine testing upon large samples of patients.
0072Although developed for the preparation of patients for surgery with the intention of preventing or reducing the incidence of post operative infection, it will be apparent to those skilled in the art from the teaching hereof that compositions according to the invention have application for treating acne and other sub dermal or sub cutaneous infections.
0073Although the method is herein described with reference to preparation of human patients for surgery it will be understood that the method is equally applicable to other animals. It will also be apparent to those skilled in the art from the teaching hereof that the invention may be performed in other ways and using different formulations without departing from the inventive concept herein disclosed.
Contents4
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO0015036A1 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| WO0141567A1 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| WO0141573A1 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| WO03034994A2 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| WO2004082649A1 | Cites | World Intellectual Property Organization (WIPO) | Examiner |
| ZA9907202A | Cites | South Africa | Examiner |
| ZA997202B | Cites | South Africa | Examiner |
| WO0015036A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO0141567A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO0141573A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9844930A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9853036A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO2004082649A1 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO03034994A2 | Cites | World Intellectual Property Organization (WIPO) | – |
| US4335115A | Cites | United States of America | – |
| US4975271A | Cites | United States of America | – |
| ZA9907202A | Cites | South Africa | – |
| SEBBEN ET AL: "Surgical antiseptics", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 9, no. 5, 1 November 1983 (1983-11-01), pages 759-765, XP022678130, ISSN: 0190-9622, DOI: 10.1016/S0190-9622(83)70192-1 [retrieved on 1983-11-01] | Non-patent | – | – |
| NIELSEN M.L. ET AL.: 'Anaerobic and aerobic skin bacteria before and after skin disinfection with chlorhexidine: An experimental study in volunteers' JOURNAL OF CLINICAL PATHOLOGY vol. 28, 1975, pages 793 - 797, XP008073497 | Non-patent | – | – |
| PAULSON D.S.: 'Efficacy of a 4% chlorhexidine gluconate as a full-body shower wash' AMERICAN JOURNAL OF INFECTION CONTROL vol. 21, 1993, pages 205 - 209, XP008073498 | Non-patent | – | – |
| RITTER M.A. ET AL.: 'The antimicrobial effectiveness of operative-site preoperative agents: a microbiological and clinical study' JOURNAL OF BONE AND JOINT SURGERY vol. 62, no. 5, 1980, pages 826 - 828, XP008073510 | Non-patent | – | – |
| S Pandey ET AL: "Development and evaluation of transdermal formulations containing metronidazole and norfloxacin for the treatment of bum wound", Indian Journal of Experimental Biology, 1 May 1999 (1999-05-01), pages 450-454, XP055296271, Retrieved from the Internet: URL:http://nopr.niscair.res.in/bitstream/1 23456789/19048/1/IJEB 37(5) 450-454.pdf [retrieved on 2016-08-18] | Non-patent | – | – |
| S PANDEY ET AL: "Development and evaluation of transdermal formulations containing metronidazole and norfloxacin for the treatment of bum wound", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, 1 May 1999 (1999-05-01), pages 450 - 454, XP055296271, Retrieved from the Internet <URL:http://nopr.niscair.res.in/bitstream/123456789/19048/1/IJEB 37(5) 450-454.pdf> [retrieved on 20160818] | Non-patent | – | Examiner |
27 members in 14 offices
Members27
| Document | Office | Kind | |
|---|---|---|---|
| AU2006246966A1 | Australia | A1 | |
| CA2608344A1 | Canada | A1 | |
| WO2006122345A1 | World Intellectual Property Organization (WIPO) | A1 | |
| TW200721974A | Taiwan Province of China | A | |
| MX2007014372A | Mexico | A | |
| EP1887864A1 | European Patent Office (EPO) | A1 | |
| KR20080019610A | Republic of Korea | A | |
| CN101175404A | China | A | |
| US2008175811A1 | United States of America | A1 | |
| JP2008540581A | Japan | A | |
| ZA200710387B | South Africa | B | |
| BRPI0612931A2 | Brazil | A2 | |
| US2011117048A1 | United States of America | A1 | |
| AU2006246966B2 | Australia | B2 | |
| EP1887864A4 | European Patent Office (EPO) | A4 | |
| CN101175404B | China | B | |
| JP2013173758A | Japan | A | |
| TWI417046B | Taiwan Province of China | B | |
| KR101413138B1 | Republic of Korea | B1 | |
| JP5892969B2 | Japan | B2 | |
| US9511017B2 | United States of America | B2 | |
| MY162625A | Malaysia | A | |
| CA2608344C | Canada | C | |
| EP1887864B1This record | European Patent Office (EPO) | B1 | |
| BRPI0612931B1 | Brazil | B1 | |
| ES2785999T3 | Spain | T3 | |
| BRPI0612931B8 | Brazil | B8 |
96 legal events, as 11 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Ip right lapsedLapsedST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)H13 | H13 | CH | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | NL | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapse because of not paying annual feesLapsedMM01 | MM01 | AT | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | BE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Publication of translation of european patent specificationUEP | UEP | AT | |
| No opposition filed against granted patent, or epo opposition proceedings concluded without decisionGrantedR097 | R097 | DE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Invalidated european patentMG4D | MG4D | LT | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| New agentNV | NV | CH | |
| Translation for ep filed (entry of ep into country)FP | FP | NL | |
| Dpma publication of mentioned ep patent grantGrantedR096 | R096 | DE | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Reference to at number (ep patent validated in austria)REF | REF | AT | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE PATENT HAS BEEN GRANTEDSTAA | STAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Intention to grant announcedINTG | INTG | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: GRANT OF PATENT IS INTENDEDSTAA | STAA | EP | |
| Amendment of ipc main classPREVIOUS MAIN CLASS: A01N0025020000R079 | R079 | DE | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: EXAMINATION IS IN PROGRESSSTAA | STAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Supplementary search report drawn up and despatchedA4 | A4 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Requests to designate patent in hong kongDE | DE | HK | |
| Request for extension of the european patent (deleted)DAX | DAX | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1887864
- Application
- 67214338
Titles3
- German
- ZUSAMMENSETZUNG FÜR DIE VORBEREITUNG EINES PATIENTEN FÜR CHIRURGISCHE EINGRIFFE
- English
- COMPOSITION FOR USE IN PREPARATION OF A PATIENT FOR SURGERY
- French
- COMPOSITION POUR PREPARER UN PATIENT A UNE INTERVENTION CHIRURGICALE
Classification
- CPC, 25
- A01N25/02
- A61K9/0014
- A61K47/10
- A61K47/20
- A61K47/32
- A61K47/38
- A61K31/085
- A61K33/18
- A61K31/327
- A61K47/22
- A61K47/08
- A61K45/06
- A61K31/155
- A61P17/00
- A61P31/00
- A61P31/02
- A61P31/04
- A61P41/00
- A61P43/00
- A61L2/18
- A61L2103/05
- A61K9/06
- A61K47/14
- A61K47/16
- A61K47/18
- IPC, 12
- A61K31 085
- A61K31 327
- A61K33 18
- A61K47 08
- A61K47 22
- A61K9 06
- A61P31 04
- A61K47 10
- A61K47 20
- A61K47 14
- A61K47 32
- A61K47 38
Designated states31
- Contracting states, 31
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Hungary
- Ireland
- Iceland
- Italy
- Liechtenstein
- Lithuania
- Luxembourg
- Latvia
- Monaco
- Netherlands (Kingdom of the)
and 7 moreShow fewer
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
- Türkiye